[Edaily Reporter YU JIN-HEE ] #Cellbion Co., Ltd, a company specializing in the development of new radiopharmaceuticals (RPT), is accelerating efforts to secure global technology licensing (L/O) and establish joint development partnerships by showcasing the clinical competitiveness of its core pipeline at Europe’s largest biotech partnering event.

Cellbion Co., Ltd. announced on the 11th that it is participating in “BIO-Europe 2026,” held in Cologne, Germany, from the 9th to the 11th (local time), and is conducting wide-ranging business development (BD) meetings with global pharmaceutical and biotech companies.

BIO-Europe is Europe’s largest technology trading fair, drawing more than 3,200 pharmaceutical and biotech companies and global investment institutions from over 60 countries worldwide. At this event, Cellbion Co., Ltd has set up its own exhibition booth, and its core business development team, led by CEO Kim Kwon, is personally engaging with major European and global pharmaceutical companies to showcase its pipeline.

The key focus of this partnering event is “Lu-177-DGUL” (pocubotide satetrasetate), a prostate cancer treatment that has entered late-stage clinical trials. In a Phase 2 clinical trial in South Korea involving patients with metastatic castration-resistant prostate cancer (mCRPC), the drug demonstrated exceptional efficacy by achieving an objective response rate (ORR) of 35.9% based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Notably, the ORR soared to 47.4% in the patient group with measurable lesions, confirming superior therapeutic efficacy compared to competing global drugs.

This new drug successfully obtained approval for its Phase 3 clinical trial plan (IND) from the Ministry of Food and Drug Safety last September and is poised to enter the main clinical trial phase. In addition, a Phase 1 clinical collaboration for a combination therapy with “Keytruda” (generic name: pembrolizumab), a blockbuster immuno-oncology drug from global pharmaceutical giant MSD, is progressing smoothly, drawing intense interest from overseas buyers regarding the potential synergistic effects of this combination.

Cellbion Co., Ltd. plans to continue follow-up discussions with the Asian network it established at “BIO-Japan 2026” last October, while using this European event as a springboard to finalize licensing agreements centered on the U.S. and Europe, as well as regional joint development discussions.

A Cellbion Co., Ltd official emphasized, “Based on the high level of interest from global big pharma companies confirmed at the recent BIO-Japan event, we are currently engaged in meaningful follow-up discussions,” adding, “At this year’s BIO Europe, we will consolidate our proven clinical data and R&D capabilities in the RPT field to achieve tangible global business results, such as technology transfers and joint development.”